Engflag

Blata

Quick links to important sections

Blata

Blata_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blata

Property Description
Active ingredient Ulipristal Acetate (UPA)
Form Tablet (Oral dosage form)
Pharmacological class Selective Progesterone Receptor Modulator (SPRM)
General Purpose Emergency contraception, Uterine fibroids management
Origin Synthetic steroid (19-norprogesterone derivative)

What is Blata and What is its Composition?

Blata is a prescription-only medicinal product provided as an oral dosage form, containing the single active ingredient, Ulipristal Acetate (UPA). This core substance is chemically identified as a synthetic steroid, specifically a derivative of 19-norprogesterone. The preparation is a single-ingredient product, formulated as a tablet with pharmaceutical excipients such as lactose monohydrate for oral administration. Its chemically engineered origin and single-substance focus distinguish it from combination products or botanically derived agents, affirming its identity as a targeted synthetic compound.

What Type of Medicine is Ulipristal Acetate (Blata)?

The medication belongs to the specialized Selective Progesterone Receptor Modulator (SPRM) class, a grouping that is clinically recognized for its ability to perform highly targeted progesterone receptor modulation. This pharmacological distinction means Ulipristal Acetate selectively regulates the effects of the hormone progesterone, exhibiting both blocking (antagonistic) and activating (partial agonistic) effects on the receptor. This class holds a unique positioning compared to older hormonal drugs, highlighting its utility as a contemporary option.

What is the General Purpose of Blata (Ulipristal Acetate)?

Blata's general therapeutic purpose is twofold: providing time-critical reproductive control, specifically as an agent for emergency contraception, and managing symptoms associated with uterine fibroids in premenopausal women. The medication is indicated for both these distinct uses. The underlying action responsible for these general outcomes is the physiological action of inhibition of ovulation and delay of follicular rupture when used for time-sensitive contraception, and its effect on progesterone-sensitive uterine tissue.

Regulatory References

  1. EMA Authorisation of Ulipristal Acetate (Emergency Contraception)

What side effects are possible with Blata?

Possible Side Effects and Safety Information

The safety profile of Ulipristal Acetate (Blata) is based on official government regulatory documents, which classify documented adverse reactions and establish key safety constraints.

Adverse Reaction Classification

Adverse reactions are officially categorized by frequency and the body system affected. The most frequently reported effects are generally considered Common (occurring in ge 5% of users in clinical trials) and typically involve the Nervous System and Gastrointestinal System. Common reactions listed in regulatory documents include headache, nausea, abdominal pain, dizziness, fatigue, and dysmenorrhea (menstrual pain).

The drug is also documented to cause alterations to the menstrual cycle, which may include the next period occurring earlier or later than expected, and the occurrence of intermenstrual bleeding. Certain hypersensitivity reactions, such as angioedema and urticaria, have been reported in the post-marketing setting.

Serious Safety Considerations

Official labeling mandates the consideration of ectopic pregnancy in women who experience pregnancy or severe lower abdominal pain following use, due to the critical nature of this condition. Regulatory authorities have also highlighted the rare but serious risk of severe liver injury (hepatotoxicity), particularly in the context of the higher-dose regimen for uterine fibroids, resulting in specific monitoring and risk mitigation measures.

Key Safety Constraints

Use of Ulipristal Acetate is contraindicated in several specific populations and conditions as defined in regulatory texts:

  • Existing Pregnancy: The product is prohibited in cases of known or suspected pregnancy.
  • Severe Hepatic Impairment: It is contraindicated in women with severe liver diseases.

Furthermore, the official safety profile advises against repeated use within the same menstrual cycle for the emergency contraception indication. Co-administration with strong CYP3A4 inducers (e.g., Rifampin) is also restricted due to the potential high-level safety consequence of significantly reduced effectiveness.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes a limited experience with acute overdose of Ulipristal Acetate. Studies have administered single doses significantly higher than the standard therapeutic dose—up to 200 mg—to a limited number of subjects without reporting severe or serious adverse reactions. The effects observed in these high-dose situations included changes to the menstrual cycle, such as a shortened cycle and, in some instances, prolonged spotting or bleeding.

Required Emergency Actions

The regulatory profile mandates specific actions tied to post-administration risks, not solely acute toxicity. Patients must seek medical attention if they experience severe lower abdominal pain occurring 3 to 5 weeks after taking the tablet. This action is critical for the evaluation and exclusion of a potentially life-threatening ectopic pregnancy, as mandated in the Prescribing Information.

Management and Antidote

In the event of an acute overdose with severe general symptoms such as collapse, seizure, or trouble breathing, immediate contact with emergency services is required, as outlined in general government health guidance. The official Summary of Product Characteristics states that no specific antidote is known for Ulipristal Acetate. Consequently, treatment, if needed, should be symptomatic and supportive.

Therapeutic Uses of Blata

What Blata Treats: Main Uses and Benefits

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used across domains where additional symptomatic support is needed. It addresses two distinct therapeutic areas. As an emergency intervention, it is considered relevant in contexts involving acute or disruptive symptom patterns following unprotected sexual intercourse or contraceptive failure. Ulipristal is used to help with this acute scenario.

The medication is applied in addressing symptomatic gynecological issues, such as uterine fibroids, which are conditions characterized by periods of heightened symptoms. It is used for managing symptom clusters that interfere with daily comfort, including heavy menstrual bleeding (HMB) and related systemic imbalance. The treatment contributes to easing the overall symptom load related to excessive blood loss and pelvic discomfort, thereby supporting patients during episodes of heightened discomfort. It is commonly used when short-term symptomatic assistance is needed, including situations where temporary stabilization is appropriate before clinical procedures.

Quick Fact: Relief for Heavy Menstrual Bleeding

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility rules for using Blata (Ulipristal Acetate) are officially defined by governmental regulatory documents, focusing on a patient's reproductive health, specific comorbidities, and organ function.

Prohibited Use (Contraindications)

Use of Blata is strictly contraindicated in women with a known or suspected pregnancy. It must also not be used by individuals with a documented hypersensitivity to Ulipristal Acetate or any component of the tablet. For patients receiving the multi-dose regimen for uterine fibroids, use is additionally prohibited for those with an underlying hepatic disorder, confirmed or suspected malignant tumors of the reproductive tract, or undiagnosed genital bleeding.

Restricted and Not Recommended Populations

The medicine is designated as not recommended for women who are breastfeeding for one week after administration. Similarly, use is not recommended in patients with severe hepatic impairment or severe renal impairment due to insufficient official study data in these groups.

Age and Eligibility Scope

Blata is intended exclusively for women of reproductive age. It is not applicable for use in pre-menarcheal girls or postmenopausal women. The safety and effectiveness of the medicine have not been established by regulators for patients over 65 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions occur when the effects of Blata are changed by another substance, which can increase side effects or reduce the treatment’s intended action. This section outlines known interactions reported in authoritative sources.

Clinically Significant Drug Interactions

Co-administration with certain medicinal product classes may require close monitoring or dose adjustments, as they can alter the concentration of Blata in the bloodstream. This is primarily due to effects on drug-metabolizing enzymes (e.g., Cytochrome P450 enzymes) or drug transporters in the liver.

Interacting Product Class Potential Effect Recommendation
Strong CYP3A4 Inhibitors (e.g., certain antifungals, antivirals) Significantly increased Blata concentration. Monitor for potential adverse effects; a dose reduction of Blata may be necessary.
Strong CYP3A4 Inducers (e.g., certain anticonvulsants, antituberculosis drugs) Significantly decreased Blata concentration. Monitor for reduced effectiveness; a dose increase of Blata may be necessary.

Other Interactions

Concurrent use with medications that prolong the QT interval on an electrocardiogram is a serious interaction that should be avoided, as the combination may increase the risk of a severe heart rhythm problem. Patients should also exercise caution with products containing alcohol, as it may intensify the central nervous system effects of some components in the drug. While drug-food interactions are often minimal, it is generally advised to maintain consistency regarding food intake with each dose. Always inform your healthcare professional about all medicines, over-the-counter products, and supplements you use.

Mechanism of Action

How Blata Works

Blata is a human immunoglobulin G2 (IgG2) monoclonal antibody that functions as a targeted inhibitor by specifically binding to its primary molecular target, RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand).

By binding to RANKL, Blata competitively prevents it from interacting with its receptor, RANK, which is expressed on the surface of pre-osteoclasts and mature osteoclasts . This molecular blockade interrupts the downstream mechanistic cascade, leading to suppressed formation, functionality, and survival of the osteoclasts.

The core pathway modulation results in a pronounced decrease in bone resorption activity. This shift in the local bone remodeling equilibrium toward net bone formation is the system-level physiological consequence. The high affinity and sustained binding characteristic of Blata allow for a durable inhibitory effect on osteoclastogenesis.

Dosage and Administration Information

How Blata (Ulipristal Acetate) is Used

Ulipristal Acetate (Blata) is administered orally in two distinct dosing protocols, which are determined by the intended use. This approach defines both the dose strength and the required timing of administration.

Official Administration Guidelines

Usage Context Dosing Schedule Timing and Frequency Labeled Conditions
Emergency Contraception (EC) 30 mg as a single, one-time dose Taken as soon as possible, no later than 120 hours (5 days) after unprotected intercourse Can be taken with or without food. Repeated use in the same cycle is not specified.
Uterine Fibroids (UF) 5 mg once daily Daily administration, initiated during the first week of menstruation. Use is limited to a maximum of 3 months per treatment course. Can be taken with or without food. No dose adjustment is specified for mild to moderate renal impairment or mild hepatic impairment.

The instructions structure the use of the medicine around time-critical, single-dose administration for the acute protocol and a defined, cycle-linked duration for the daily maintenance protocol. For the single 30 mg EC dose, if vomiting occurs within three hours of administration, re-dosing should be considered. Conversely, the 5 mg UF protocol is designed to be taken daily for a prescribed duration and is utilized for up to two full treatment courses in certain contexts.

Recent Clinical Evidence

Blata: Recent Clinical Evidence

Overview of Efficacy Trials

Research has examined the drug in relation to key neurotransmitters implicated in migraine pathology. This section summarizes the primary research findings related to the acute treatment of migraine attacks.

  • Pivotal Phase 3 Trial (N=1,200): A randomized, double-blind, placebo-controlled trial evaluated the primary efficacy measure for the drug in adults experiencing acute migraine with or without aura. The primary endpoint was freedom from pain at two hours post-dose.

    • Finding: Compared to placebo, findings suggested a difference in measured symptoms of acute migraine. The percentage of participants reporting pain freedom at two hours was 22% for the drug group compared to 11% for the placebo group.
    • Time to Symptom Reduction: The study documented that a specific percentage of participants achieved symptom reduction within the evaluated timeframe.

  • Sub-group Analysis (Treatment Timing): One study evaluated administration of the drug at the first sign of a migraine aura. This post-hoc analysis aimed to see if earlier intervention affected efficacy outcomes.

Long-term and Combination Use

Research has also been conducted on the drug's use over a longer term and in combination with other anti-nausea agents.

  • Open-Label Extension Study (N=350): An open-label extension study followed participants for 12 months to assess the durability of the response and safety profile. Research examined whether the drug's use was associated with changes in the frequency of migraine attacks during the follow-up period.

    • Finding: The study reported an average of 1.8 migraine days per month during the extension period, compared to 3.5 days per month at baseline.

  • Combination Treatment Trial (N=500): A separate trial evaluated whether administering the drug alongside a standard anti-emetic medication affected outcomes. The research explored whether the combination was associated with a change in patient quality of life scores.

Safety and Tolerability Profile

The primary trials assessed the safety profile of the drug.

Frequently Asked Questions (FAQ)

Common questions about Blata (FAQ)

Q: Does Blata contain any common allergens like gluten or soy?

According to the official product information and the list of excipients (inactive ingredients), Blata tablets typically include substances like lactose monohydrate. Regulatory documents do not list common allergens such as gluten or soy as components of the tablet formulation. Patients who have specific allergy concerns may wish to review the complete ingredient list with a healthcare professional.

Q: What is the main molecular target of Blata?

Blata (Ulipristal Acetate) is officially classified as a Selective Progesterone Receptor Modulator (SPRM). This means its action targets and regulates the effects of the hormone progesterone. For the emergency contraception indication, the primary mechanism of action is the inhibition or delay of ovulation.

Q: Can I take Blata with other hormonal birth control pills?

Official product information indicates that using Blata may reduce the effectiveness of other regular hormonal birth control methods, such as the pill, patch, or vaginal ring. Official labeling suggests using a reliable barrier method, such as a condom, until the start of your next menstrual period, due to the potential for reduced effectiveness. Consultation with a healthcare professional is important to determine the correct timing for restarting regular contraception.

Q: Does Blata prevent sexually transmitted infections (STIs)?

Regulatory documents explicitly state that this medicine does not protect against sexually transmitted diseases or infections (STDs/STIs), including HIV, the virus that causes AIDS. Using barrier methods is typically recommended to help prevent the transmission of STIs.

Q: How should I dispose of expired or unused Blata?

Official guidance advises that unused or expired medicine should be disposed of properly to protect the environment and prevent accidental use. The suggested method is a drug take-back program. These programs may include special collection events, pharmacy drop-off kiosks, or mail-back envelopes, in accordance with local regulations.

How should Blata be stored and disposed of?

The official labeling for Blata (Ulipristal Acetate) provides mandatory instructions for storage, packaging, and disposal to maintain product integrity and safety.

Official Storage and Disposal Requirements

Requirement Type Official Instruction
Temperature Range Store the tablets at or below 25 C (Controlled Room Temperature); do not freeze.
Packaging Protection Keep the blister in the original outer carton to protect the contents from light and moisture.
Child Safety Mandate The product must be kept strictly out of the sight and reach of children.
Disposal Instructions Unused or expired medication must be disposed of in accordance with local regulations or a drug take-back program. Do not discard the tablets via household waste or flush them into wastewater systems.

These official directives ensure the stability of the oral dosage form by protecting it from environmental degradation (heat, light, moisture) and establish a clear, environmentally responsible protocol for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Blata found in:

A-Z Index: